Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
Status:
Terminated
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Patients will receive budesonide or placebo for the treatment of active lymphocytic colitis.
This study includes stool collections, blood draws, weekly questionnaires and a
sigmoidoscopy. The study hypothesis is that budesonide will be safe and effective compared
with placebo for the treatment of diarrhea in lymphocytic colitis.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
AstraZeneca National Center for Research Resources (NCRR)